Table 2.
Primary and secondary trial outcomes adjusted for gender
| Outcome | Sample | n | Cluster-level geometric mean prevalence | RR (95% CI) | P value | CoV | |
|---|---|---|---|---|---|---|---|
| Control | Intervention | ||||||
| Primary outcome | |||||||
| VS | YWH | 1,217 | 38.3% | 41.3% | 1.07 (0.88–1.30) | 0.47 | 0.24 |
| Secondary outcomes (aligned to UNAIDS 90-90-90 targets) | |||||||
| Know the HIV diagnosis | YWH | 1,226 | 51.5% | 51.6% | 0.99 (0.76–1.28) | 0.93 | 0.25 |
| Taking ART | YWH who know their HIV status | 650 | 96.3% | 87.3% | 0.91 (0.83–0.99) | 0.025 | 0.08 |
| VS | YWH taking ART | 599 | 52.6% | 62.7% | 1.19 (1.02–1.39) | 0.033 | 0.06 |
YWH were defined as participants who either had a positive ELISA test on a DBS sample or self-reported as HIV positive.
YWH who know their HIV status were defined as YWH who either self-reported as HIV positive or had ARVs detected in their DBS sample.
YWH taking ART were defined as YWH who either self-reported as taking ART or had ARVS detected in their DBS sample.
CoV, coefficient of variation.